Physician profile
Erwin Maseelall
NPI 1982604013
$3,423.03
in general payments reported to CMS, 2019-2025
19 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $411 · 2021: $572 · 2022: $110 · 2023: $631 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Education: $17.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.78 |
| Education | $17.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $363.87 | 2021-2023 | Tyvaso |
| Janssen Pharmaceuticals, INC | $317.07 | 2019-2020 | |
| Pfizer INC. | $292.78 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $241.16 | 2023 | Camzyos |
| Abbvie INC. | $239.26 | 2021-2023 | |
| Allergan, INC. | $235.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $217.39 | 2019-2021 | |
| Amarin Pharma, INC. | $212.04 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $179.74 | 2019 | |
| Insmed, INC. | $148.56 | 2025 | Brinsupri, Arikayce |
| Astellas Pharma US INC | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $123.90 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $122.18 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $121.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.99 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.05 | 2020 | |
| Lilly USA, LLC | $92.16 | 2019 | |
| Novo Nordisk INC | $88.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Maseelall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.